The Latest Cardiac and Vascular News
— Leaders in the fields of RNA and cardiovascular disease join HAYA to advance its pipeline of therapeutics targeting long non-coding RNAs — LAUSANNE, Switzerland–(BUSINESS WIRE)–HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), today announced the formation and members of its […]
Enrollment in the REVERSE-IT global Phase 3 trial from clinical sites in China expected to begin later in 2021 MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the Investigational New […]
Smaller Footprint, Improved User Experience and Lower Cost to Drive Adoption REDWOOD CITY, CA / ACCESSWIRE / August 9, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the submission […]
SANTA CLARA, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2021. Recent Highlights Recognized revenue of $55.9 million […]
CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the American Medical Association (AMA) CPT Editorial Panel issued a new Category III CPT® code, effective July 1, 2021, for its TherOx® SuperSaturated Oxygen (SSO2) Therapy. The code, 0659T (transcatheter intracoronary infusion of […]
− Full Study Enrollment Completed Well Ahead of Schedule − CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of cardiomyopathy in patients […]
SAN FRANCISCO, Aug. 05, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended June 30, 2021. Second Quarter 2021 Financial Highlights Revenue was $81.3 million, a 59.8% […]
ANDOVER, Mass., Aug. 5, 2021 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2021. Recent Highlights Net revenue of $8.2 million in the second quarter of 2021, representing […]
Submission of NDA for Omecamtiv Mecarbil on Track to Occur in 2H 2021 Positive Results from REDWOOD-HCM Support Progression of Aficamten (CK-274) to Pivotal Phase 3 Trial in Patients with Obstructive Hypertrophic Cardiomyopathy Expected to Start in Q4 Pivotal Phase 3 Trial of Reldesemtiv in Patients with ALS Now Enrolling More […]
WARRINGTON, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the second quarter ended June 30, 2021 and provided key business updates. “I am […]
